Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Biol Psychiatry. 2013 Apr 19;74(5):367–374. doi: 10.1016/j.biopsych.2013.02.027

Figure 4. YM-01 reduces tau levels by a mechanism dependent on Hsc70 and the proteasome.

Figure 4

(A) Representative Western blots from HeLa cells over-expressing tau, treated with YM-01 and the proteasome inhibitor epoxomycin (Epox) (400 nM) for 4 hrs. Results are the average of triplicates and the error bars represent standard deviations. (B) Representative Western blots of neuronal M17 cells treated with YM-01. Quantification of tau levels is shown as a percentage of vehicle (0) treated cells ± standard deviation after GAPDH normalization.